Progressive Supranuclear Palsy (PSP) Trials
ClinicalTrials.gov ID: NCT06355531 – PROSPER
Purpose: To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also assesses safety and tolerability.
Intervention: FNP-223, an experimental drug targeting PSP pathology.
Locations: International sites; primary contact via Ferrer MedInfo, Spain.
Sponsor: Ferrer Internacional S.A.
Eligibility: Ages 50–80; diagnosis of possible/probable PSP Richardson’s Syndrome ≤3 years from symptom onset; MoCA ≥23; full PSPRS ≤40; able to ambulate with minimal assistance; must have a caregiver or study partner.
Recruitment Status: Recruiting (July 2024 – November 2026).
ClinicalTrials.gov ID: NCT02605785
Purpose: To study tau protein accumulation in PSP using advanced imaging (PET/MRI) for better understanding of disease pathology.
Intervention: Imaging study (no drug intervention).
Locations: Rochester, Minnesota, USA
Sponsor: Mayo Clinic
Eligibility: PSP diagnosis; able to undergo imaging.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT06588673
Purpose: To assess whether structured art therapy improves quality of life, mood, and cognitive engagement in PSP patients.
Intervention: Non-drug art therapy program.
Locations: Nashville, Tennessee, USA
Sponsor: Vanderbilt University Medical Center
Eligibility: PSP diagnosis; ability to participate in art therapy sessions.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT04468932
Purpose: To test if repetitive transcranial magnetic stimulation (rTMS) can improve motor and cognitive function in PSP patients.
Intervention: rTMS applied to the brain over multiple sessions.
Locations: Portland, Oregon, USA
Sponsor: Oregon Health & Science University
Eligibility: PSP diagnosis; able to tolerate rTMS.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT03638505
Purpose: Observational study measuring patient quality of life and caregiver burden in PSP.
Intervention: Questionnaires and functional assessments (no drug).
Locations: Marseille, France
Sponsor: Assistance Publique – Hôpitaux de Marseille
Eligibility: PSP diagnosis; must have a caregiver.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT06647641 – CurePSP Genetics Program
Purpose: To collect genetic and biomarker data to study risk factors, progression, and biology of PSP.
Intervention: DNA sampling and biomarker collection.
Locations: Boston, Massachusetts, USA
Sponsor: CurePSP Foundation
Eligibility: PSP diagnosis; willing to provide genetic samples.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT05956834
Purpose: To evaluate wearable sensors and digital tools for remote monitoring of PSP, CBD, and related syndromes.
Intervention: Digital and wearable devices to track symptoms.
Locations: Baltimore, Maryland & Boston, Massachusetts, USA
Sponsor: Johns Hopkins University
Eligibility: PSP or CBD diagnosis; able to use wearable devices.
Recruitment Status: Recruiting
Multiple System Atrophy (MSA) Trials
ClinicalTrials.gov ID: NCT06063950 – TOPAS-MSA
Purpose: To assess safety and efficacy of TEV-56286 in MSA patients.
Intervention: TEV-56286, a novel therapeutic compound.
Locations: Multi-center, international
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Eligibility: MSA diagnosis; meet general health and symptom criteria.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT06356676 – SPRITE
Purpose: To evaluate the safety and preliminary efficacy of Aleeto in MSA patients.
Intervention: Aleeto (experimental drug)
Locations: Multi-center, international
Sponsor: AskBio
Eligibility: MSA diagnosis; meet inclusion/exclusion criteria.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT05104463 – MASCOT
Purpose: To test Lu AF82422, an anti-alpha-synuclein antibody, in MSA patients for efficacy and safety.
Intervention: Lu AF82422 (monoclonal antibody)
Locations: Multi-center, international
Sponsor: H. Lundbeck A/S
Eligibility: MSA diagnosis; general health criteria
Recruitment Status: Recruiting
Dementia With Lewy Bodies (DLB) Trials
ClinicalTrials.gov ID: NCT06815965
Purpose: To evaluate safety, tolerability, and pharmacokinetics of neflamapimod in DLB patients.
Intervention: Neflamapimod, a p38 kinase inhibitor
Locations: Paris & Strasbourg, France
Sponsor: EIP Pharma, Inc.
Eligibility: Age ≥55, probable DLB, MoCA ≥18, stable cholinesterase inhibitor therapy if applicable, normal/corrected vision and hearing, reliable caregiver.
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT04961481
Purpose: To test whether rTMS improves cognition in DLB patients.
Intervention: rTMS (non-invasive brain stimulation)
Locations: Shanghai, China
Sponsor: Shanghai Mental Health Center
Eligibility: DLB diagnosis; able to undergo rTMS
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT06956308
Purpose: To assess safety and efficacy of AR1005 in patients with Lewy Body Disease.
Intervention: AR1005 (neuroprotective biologic)
Locations: Multi-center
Sponsor: Arbor Pharmaceuticals
Eligibility: Diagnosis of Lewy Body Disease; meet inclusion criteria
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT07100967
Purpose: To investigate the safety and effects of non-invasive low-intensity focused ultrasound stimulation (tFUS) in mild Lewy Body Dementia.
Intervention: tFUS device
Locations: Beijing, China
Sponsor: Tsinghua University
Eligibility: Mild Lewy Body Dementia diagnosis
Recruitment Status: Recruiting
ClinicalTrials.gov ID: NCT05712700
Purpose: To evaluate pulsed electromagnetic field therapy for dementia patients.
Intervention: Pulsed electromagnetic field device
Locations: Houston, Texas, USA
Sponsor: University of Texas Health Science Center, Houston
Eligibility: Diagnosis of dementia; able to comply with treatment
Recruitment Status: Recruiting
Corticobasal Syndrome (CBS) / Corticobasal Degeneration (CBD) Trials
ClinicalTrials.gov ID: NCT07104246 – ST-CBS
Purpose: To test Scrambler Therapy for pain relief in patients with CBS.
Intervention: Scrambler Therapy device (electrical stimulation delivering “non-pain” signals)
Locations: Kansas City, Kansas, USA
Sponsor: University of Kansas Medical Center
Eligibility: CBS diagnosis; experiencing CBS-related pain; able to provide informed consent
Recruitment Status: Recruiting
Parkinsonian Syndromes / Mixed Trials
ClinicalTrials.gov ID: NCT07118434
Purpose: To use AI to improve the accuracy and sensitivity of the acute levodopa challenge test for Parkinson’s disease, PSP, and MSA.
Intervention: AI software analyzing levodopa response paired with the standard challenge test
Locations: New York, NY, USA
Sponsor: NYU Langone Health
Eligibility: Diagnosis of PD, PSP, or MSA; eligible for levodopa challenge test
Recruitment Status: Recruiting
Donate
